Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure

Gene Therapy

Volumn 23, Issue 3, 2016, Pages 313-319

  Greenberg, B ^a   Butler, J ^b   Felker, G M ^c   Ponikowski, P ^d   Voors, A A ^e   Pogoda, J M ^f   Provost, R ^f   Guerrero, J ^f   Hajjar, R J ^g   Zsebo, K M ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f Celladon Corporation   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Biovest Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLATE MOFETIL; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; RAPAMYCIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS 1; ADENO ASSOCIATED VIRUS SEROTYPE 1; ADULT; AGED; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; FEMALE; GENE TRANSFER; HEART FAILURE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MINIPIG; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SEROCONVERSION; VIRAL GENE THERAPY; ANIMAL; ANIMAL MODEL; CLINICAL TRIAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; PIG;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; MODELS, ANIMAL; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SWINE; SWINE, MINIATURE;

EID: 84960101848     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.109     Document Type: Article

References (23)

1. Pleger SV, Brinks H, Ritterhoff J, Raake P, Koch WJ, Katus HA, et al. Heart failure gene therapy: the path to clinical practice. Circ Res. 2013; 113: 792-809.
2. Du L, Kido M, Lee DV, Rabinowitz JE, Samulski RJ, Jamieson SW, et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-Associated viral vectors. Mol Ther. 2004; 10: 604-608.
3. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009; 15: 171-181.
4. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac diseases (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum CA2 +-ATPase in patients with advanced heart failure. Circulation. 2011; 124: 304-313.
5. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, et al. Long-Term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure. Analysis of recurrent cardiovascular events and mortality. Circ Res. 2014; 114: 101-108.
6. Greenberg B, Yaroshinsky A, Zsebo KM, Butler J, Felker GM, Voors AA, et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID-2 trial (Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b). JACC Heart Fail. 2014; 2: 84-92.
7. Manno CS, Arruda VR, Pierce GF, Glader B, Ragni M, Rasko J, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006; 12: 342-347.
8. Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, et al. Sustained alpha-sarcoglycan gene expression following gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol. 2010; 68: 629-638.
9. Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-Adenoassociated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013; 24: 59-67.
10. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-Associated viruses. J Infect Dis. 2009; 199: 381-390.
11. van der Marel S, Comijn EM, Verspaget HW, van Deventer S, van den Brink GR, Petry H, et al. Neutralizing antibodies against adeno-Associated viruses in inflammatory bowel disease patients: implications for gene therapy. Inflamm Bowel Dis. 2011; 17: 2436-2442.
12. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, et al. Humoral and cellular capsid-specific immune responses to adeno-Associated virus type 1 in randomized healthy donors. J Immunol. 2012; 188: 6418-6424.
13. Liu Q, Huang W, Zhao C, Zhang L, Meng S, Gao D, et al. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector. J Med Virol. 2013; 85: 1550-1556.
14. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, et al. Adeno-Associated virus antibody profiles in newborns, children and adolescents. Clin Vaccine Immunol. 2011; 18: 1586-1588.
15. Harbison CE, Weichert WS, Gurda BL, Chiorini JA, Agbandje-McKenna M, Parrish CR. Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-Associated virus serotypes 1 and 5. J Gen Virol. 2012; 93: 347-355.
16. Erles K, Seböková P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-Associated virus (AAV). J Med Virol. 1999; 59: 406-411.
17. Eisner D, Caldwell J, Trafford A. Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later. Circ Res. 2013; 113: 958-961.
18. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA. 2009; 106: 16363-16368.
19. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, et al. Phase 2 clinical trial of a recombinant adeno-Associated viral vector expressing a1-Antitrypsin: interim results. Hum Gene Ther. 2011; 22: 1239-1247.
20. Mingozzi F, Chen Y, Murphy SL, Edmonson SC, Tai A, Price SD, et al. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther. 2012; 20: 1410-1416.
21. Chicoine LG, Montgomery CL, Bremer WG, Shontz KM, Griffin DA, Heller KN, et al. Plasmapharesis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther. 2014; 22: 338-347.
22. Monteilhet V, Saheb S, Boutin S, Leborgne C, Veron P, Montus MF, et al. A 10 patient case report on the impact of plasmapharesis upon neutralizing factors against adeno-Associated virus (AAV) types 1, 2, 6 and 8. Mol Ther. 2011; 19: 2084-2091.
23. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, et al. Epitope mapping of human anti-Adeno-Associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol. 2000; 74: 1761-1766.